BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Insilico Medicine Launches First Human Study for ISM5411, Oral PHD Inhibitor for IBD

ISM5411 is an oral, PHD-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes. ISM5411 is ...

December 05, 2023 | News

XtalPi and HKU's Biomedical Instrumentation Centre Partner to Boost Deep Tech Commercialization

XtalPi, a leading global technology company, is renowned for its expertise in integrating physics-based computation, artificial intelligence (AI), and robo...

November 28, 2023 | News

Viva Biotech Secures Approximately US$ 210 Million Funding

Before, the publicly listed company at the group level had already secured approximately US$ 60 million in convertible bond financing, which will...

November 21, 2023 | News

WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange

WuXi XDC issued a total of 178,446,000 shares under the global offering at an offer price of HK$20.60 per share (being the high-end of the indica...

November 20, 2023 | News

AXA Introduces "Better She"

AXA Hong Kong and Macau is proud to introduce the "Better She" Programme ("Better She"), the first menopause health management programm...

November 15, 2023 | News

Menarini Group and SciClone Pharma Partner to Bring ORSERDU® to China for Advanced Breast Cancer

ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations,...

November 08, 2023 | News

Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction

Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading bioph...

November 02, 2023 | News

WuXi XDC and HKSTP Collaborate to Boost Bioconjugate Drug Industry in Hong Kong

Hong Kong Science and Technology Parks Corporation (HKSTPC) and WuXi XDC signed a cooperation framework agreement to jointly promote ...

October 18, 2023 | News

MediLink and BioNTech Partner for Advanced Anti-Cancer Drug

Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of ...

October 13, 2023 | News

Akeso and RemeGen Team Up for Gastric Cancer Therapy Study

On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/0...

October 02, 2023 | News

Rimegepant Now Available in Hong Kong as First Asian Market for Migraine Management

"As the first market in Asia, we are pleased to bring to Hong Kong this medication for migraine, as we understand how migraine can adversely...

October 02, 2023 | News

Hong Kong's Akeso Receives FDA IND Clearance for AK117 in MDS Combo with Azacitidine

The upcoming study, known as a randomized, double-blind, global multi-center Phase II study, is set to be conducted in the United States. Based on th...

September 29, 2023 | News

Key Takeaways from BIOHK2023 Leave a Lasting Impression

We were honored to have insightful keynote speeches delivered by renowned individuals, including: Mr. CY Leung, Vice Chairman of CPPCC Dr. Bruce B...

September 28, 2023 | News

Pfizer's Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong

First pneumococcal conjugate vaccine that fights against 20 serotypes leading to most of the invasive pneumococcal diseases and pneumonia[2],[3] &md...

August 11, 2023 | News

Stay Connected